<DOC>
	<DOCNO>NCT01198145</DOCNO>
	<brief_summary>RATIONALE : Sulfasalazine may relieve diarrhea patient cancer undergo pelvic radiation therapy . PURPOSE : This randomized phase III trial study sulfasalazine see well work prevent acute diarrhea patient cancer undergo pelvic radiation therapy .</brief_summary>
	<brief_title>Sulfasalazine Preventing Acute Diarrhea Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether sulfasalazine effective reduce acute treatment-related diarrhea patient receive pelvic radiotherapy measure NCI CTC v4.0 patient receive pelvic external-beam radiotherapy adjuvant primary treatment malignancy . Secondary - To determine whether sulfasalazine reduce chronic treatment-related bowel dysfunction follow completion therapy . - To determine whether sulfasalazine cause toxicity situation . Tertiary - To bank blood product future study , part ongoing research NCCTG study ( Mayo Clinic Rochester ) . ( Translational ) OUTLINE : This multicenter study . Patients stratify accord history anterior resection rectum ( yes v ) ; total plan cumulative dosing , include boost field external-beam radiotherapy ( 4500-5350 cGy v &gt; 5350 cGy ) ; concurrent radiosensitizing fluorouracil , capecitabine , oxaliplatin ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral sulfasalazine twice daily radiotherapy* 4 week completion radiotherapy . - Arm II : Patients receive oral placebo twice daily radiotherapy* 4 week completion radiotherapy . NOTE : *Patients must start study treatment third radiotherapy fraction . Patients may undergo blood sample collection baseline weekly radiotherapy . All patient complete quality life bowel function questionnaire baseline , weekly radiotherapy , 6 week completion radiotherapy . After completion radiotherapy , patient follow 6 week 12 24 month .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer support use radiotherapy pelvis No current prior metastases beyond pelvic regional lymph node Planning receive course continuous definitive adjuvant externalbeam radiotherapy minimum dose 4500 cGy without fluorouracil , capecitabine , oxaliplatin Planned course pelvic radiotherapy must fall within follow parameter : Pelvis must encompass plan radiotherapy field Superior border may lie superior L45 interspace may inferior inferior aspect sacroiliac joint Portions rectum may special blocking , depend upon disease site Total plan dose central axis midplane ( APPA parallel oppose field ) isocenter ( 3 4field technique ) pelvic field must lie 45005300 cGy ( inclusive ) * Subsequent completion treatment pelvic field , boost primary tumor tumor bed may plan Planned treatment give 45 time per week onetreatmentperday basis Daily dose ( specified central axis midplane isocenter multifield technique ) must lie 170210 cGy ( inclusive ) per day* NOTE : *For institution use midplane isocenter point specification dose , necessary determine dose accord method specify order determine patient eligibility . No perineal irradiation plan ( e.g. , anal cancer patient , patient abdominalperineal resection ) No brachytherapy plan completion externalbeam radiotherapy No plan splitcourse radiotherapy PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 6 month Hemoglobin ≥ 10.0 g/dL Leukocytes ≥ 3,500/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Willing provide blood specimen require study ( Mayo Clinic Rochester patient ) Able complete questionnaire alone assistance No history inflammatory bowel disease No history gastrointestinal genitourinary obstruction porphyria No history G6PD deficiency No history irritable bowel syndrome No history blood dyscrasia No history severe allergy asthma No history hepatic renal disease No diarrhea ≥ grade 3 , rectal bleeding , abdominal cramping , incontinence stool within past week No medical condition may interfere ability receive study treatment No known allergy sulfasalazine , sulfa medication , salicylate , know component drug formulation PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior pelvic radiotherapy No prior abdominalperineal resection , Hartmann procedure , surgical procedure leave patient without function rectum No plan use leucovorin cytotoxic chemotherapeutic agent concurrent radiotherapy ( except fluorouracil , capecitabine , oxaliplatin ) No concurrent sulfasalazine No concurrent digoxin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>diarrhea</keyword>
	<keyword>gastrointestinal complication</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>